北京华芢生物技术

Huaren Biotech is a clinical-stage biopharmaceutical company based in Beijing, China, specializing in the development of recombinant protein therapeutics for wound healing and tissue repair. The company leverages its proprietary platelet-derived growth factor (PDGF) technology platform to address significant unmet medical needs in chronic wound management and regenerative medicine. Its lead candidate, Pro-101-11, is a recombinant human PDGF-BB gel currently in Phase 3 clinical trials for the treatment of diabetic foot ulcers. Beyond its core focus on dermatology, Huaren Biotech is expanding its pipeline into ophthalmology and medical aesthetics. The company recently filed for an initial public offering on the Hong Kong Stock Exchange to accelerate its clinical development and commercialization efforts.